Cystic Fibrosis: Vanzacaftor/Tezacaftor/Deutivacaftor Therapy

We are studying a new combination therapy for cystic fibrosis in individuals aged one year and older. The trial aims to evaluate its long-term safety and effectiveness.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Tezacaftor
Tezacaftor is a substance that helps correct a faulty protein in cystic fibrosis, improving lung function and reducing mucus buildup.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Alyftrek
Vanzacaftor
Deutivacaftor

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Hospices Civils De Lyon
Service de Pédiatrie, Allergologie, Mucoviscidose
Bron, France
Assistance Publique Hopitaux De Paris
Hôpital Necker - Enfants Malades, Service de Pneumologie et Allergologie Pédiatriques
Montrouge, France
Charite Universitaetsmedizin Berlin KöR
Department of Pediatric Pulmonology, Immunology and Critical Care Medicine
Berlin, Germany

Sponsor: Vertex Pharmaceuticals Inc.
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.